The Current Status of Treatment for Oligometastatic Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 May 2025 | Viewed by 1580
Special Issue Editor
Special Issue Information
Dear Colleagues,
The emergence of effective systemic therapies, such as immune checkpoint inhibitors and molecular-targeted therapies, along with the advent of precision medicine, has improved survival outcomes in advanced non-small-cell lung cancer. However, only a fraction of cases can avoid recurrence or progression. In this context, there has been increased awareness of the disease state, known as "oligometastases", and a multidisciplinary treatment strategy combining systemic and local ablative therapies has been explored for certain patients, potentially aiming to develop a cure.
The primary local treatment for oligometastatic lung cancer is radiation therapy, with high-precision radiation therapy being central to local ablative therapy in several ongoing randomized phase III trials. Studies exclusively focused on surgical treatment for oligometastatic lung cancer have been limited, although there are situations where surgical treatment is prioritized for local lesions. It is essential to clarify the criteria for local ablative therapy and to classify oligometastatic states systematically to develop an effective oligometastatic lung cancer treatment strategy in the future.
Dr. Yoshihisa Shimada
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oligometastases
- oligo-recurrence
- lung cancer
- local ablative therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
